View 1997-09-10
Prospective Grant of Exclusive License: For Nucleic Acid-Based Vaccines and Therapeutics Only written comments and/or applications for a license which are received by NIH on or before December 9, 1997 will be considered.
View 1997-08-20
Prospective Grant of Exclusive License: Biomedical Uses of Topoisomerase I Inhibitors Including Camptothecin and Derivatives for Retroviral Applications Including Human Immunodeficiency Virus (HIV) Only written comments and/or applications for a license which are received by NIH on or before October 20, 1997 will be considered.
View 1997-08-11
Prospective Grant of Exclusive License: Diagnostic Methods Derived From the Human Metastasis Suppressor Gene KAI1 Only written comments and/or applications for a license which are received by NIH on or before October 10, 1997.
View 1997-08-11
Prospective Grant of Exclusive License: New Brefeldin a Derivatives Only written comments and/or applications for a license which are received by NIH on or before October 10, 1997, will be considered.
View 1997-08-11
Notice of CRADA Opportunities Inquiries regarding scientific matters may be forwarded at any time. Confidential CRADA proposals, preferably one page or less, must be submitted to NCI on or before October 10, 1997. Guidelines for preparing full CRADA proposals will be communicated shortly thereafter to all respondents who have been selected.
View 1997-05-27
Prospective Grant of Limited Exclusive License: Radioimmunotherapy Utilizing Bismuth 213 and Monoclonal Antibodies Having Binding Specificity to Tag-72 and Human Carcinomas Only written comments and/or applications for a license which are received by NIH on or before July 28, 1997 will be considered.
View 1997-05-27
Opportunity for a Cooperative Research and Development Agreement (CRADA) and Licensing Opportunity for Testosterone Bucyclate In view of the high priority for developing and commercializing testosterone bucyclate, all proposals must be received no later than June 26, 1997 for priority consideration.
View 1997-05-27
Prospective Grant of Exclusive License: Vaccine for Malaria
View 1997-05-22
Prospective Grant of Exclusive License: Prophylactic Use of Pneumococcal Surface Adhesin A Protein as a Vaccine 09/17/91 Domestic Status: Patent No.: 5,422,427 Issue Date: 06/06/95
View 1997-04-29
Prospective Grant of Exclusive License: Treatment of Cancer Using Human Chorionic Gonadotropin (hCG)
View 1997-04-10
Propspective Grant of Exclusive License: Method of Identifying Persons Susceptible to Autoimmune Neuropsychiatric Disorders
View 1997-04-01
National Institute of Child Health and Human Development: Opportunity for a Cooperative Research and Development Agreement (CRADA) for the Development of a Microbial Screen for Anti-Virals Targeting PKR or Inhibitors of PKR CRADA proposals should be received on or before July 30, 1997 for priority consideration. However, CRADA proposals submitted thereafter will be considered until a suitable CRADA Collaborator is selected.
View 1997-03-21
Prospective Grant of Exclusive License: Replicating Tumoricidal Viral Therapy for Cancer Applications
View 1997-03-19
Prospective Grant of Exclusive License: Method of Treating Established Colitis Using Antibodies Against IL-12
View 1997-03-17
National Heart, Lung, and Blood Institute
View 1997-03-11
Prospective Grant of Exclusive License: IL-13 Receptor Specific Chimeric Proteins and Uses Thereof
View 1997-02-26
National Cancer Institute and the Food and Drug Administration: Opportunity for a Cooperative Research and Development Agreement (CRADA) for the Scientific and Commercial Development of Soluble Tat Peptide Analogs for the Inhibition of HIV Transcription and Viral Replication In view of the important priority of developing new agents for the treatment of infectious disease and related malignancies, interested parties should notify this office in writing no later than April 28, 1997. Respondents will then be provided an additional 30 days for the filing of formal proposals.
View 1997-02-13
Prospective Grant of Exclusive License: Diagnostic Test for Alzheimer's Disease
View 1997-02-13
Government-Owned Inventions; Availability for Licensing
View 1997-02-13
National Institute of Child Health and Human Development: Licensing Opportunity and/or Opportunity for a Cooperative Research and Development Agreement (CRADA) for Novel Progesterone Antagonists and Pharmaceutical Compositions Thereof There is no deadline by which license applications must be received. CRADA proposals must be received on or before May 14, 1997.
View 1997-02-07
Prospective Grant of Exclusive License: Vaccines for Dengue and Other Flaviviruses
View 1997-02-07
Prospective Grant of Exclusive License: Particle-Medicated Gene Delivery DNA Vaccines Against Dengue and Other Flavivirus Infections
View 1997-01-29
Medicare and Medicaid Programs; Small Business Innovation Research Grants for Fiscal Year 1997 Grant applications must be submitted by April 29, 1997, in order to be considered under the fiscal year (FY) 1997 annual funding cycle.
View 1997-01-22
Government-Owned Inventions; Availability for Licensing
View 1997-01-15
National Cancer Institute; Opportunity for a Cooperative Research and Development Agreement (CRADA) for the Scientific and Commercial Development of Monoclonal Antibodies to a Tumor-Specific Growth Factor for the Diagnosis and Prognosis of Premalignant Lesion and Cancer
